PictorLabs Inc

United States - Los Angeles, California

• 19/09/2024
• Series B
• $30,000,000

PictorLabs, Inc. is a digital pathology company developing an AI-powered virtual staining platform to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence, and health-tech product development, the Company is reimagining existing histopathology workflows, accelerating clinical and diagnostic results, and improving process sustainability. From a single unstained tissue sample, PictorLabs’ proprietary platform can produce an unlimited number of virtual stains that are indistinguishable from analogous chemical stains. PictorLabs is developing products that replicate standard of care stains and is creating specialized virtual biomarker stains for indications in which there is a large demand for novel and accelerated diagnostic tests. To learn more, visit https://pictorlabs.ai/

Related People

Yair RivensonFounder

United States - Los Angeles, California

Yair Rivenson, PhD, is the CEO and Co-Founder of Pictor Labs. He has lead Pictor’s R&D efforts, engineering and business operations, and recruitment strategy since it broke ground in October 2020. Dr. Rivenson has lead the efforts to transform the core virtual staining intellectual property to a working prototype and then to a commercialized product.
Prior to taking an active role in Pictor Labs, Dr. Rivenson served as a full-time adjunct and research professor at the University of California, Los Angeles, Department of Electrical and Computer Engineering. There he developed the core technologies that would become Pictor’s foundation.
Dr. Rivenson’s IP portfolio includes 10 pending patents, over 65 co-authored journal publications and more than 110 peer-reviewed conference presentations.

LinkedIn https://www.linkedin.com/in/yair-rivenson-8443b012/